现在的位置: 首页时讯速递, 进展交流>正文
[Clin Infect Dis发表论文]:法匹拉韦治疗无症状或非复杂性新冠肺炎门诊患者
2023年01月29日 时讯速递, 进展交流 [Clin Infect Dis发表论文]:法匹拉韦治疗无症状或非复杂性新冠肺炎门诊患者已关闭评论

Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial 

Marisa Holubar,  Aruna Subramanian,  Natasha Purington,  et al

Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1883–1892, https://doi.org/10.1093/cid/ciac312

Abstract

Background

Favipiravir, an oral, RNA-dependent RNA polymerase inhibitor, has in vitroactivity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite limited data, favipiravir is administered to patients with coronavirus disease 2019 (COVID-19) in several countries.

Methods

We conducted a phase 2, double-blind, randomized controlled outpatient trial of favipiravir in asymptomatic or mildly symptomatic adults with a positive SARS-CoV-2 reverse-transcription polymerase chain reaction assay (RT-PCR) within 72 hours of enrollment. Participants were randomized to receive placebo or favipiravir (1800 mg twice daily [BID] day 1, 800 mg BID days 2–10). The primary outcome was SARS-CoV-2 shedding cessation in a modified intention-to-treat (mITT) cohort of participants with positive enrollment RT-PCRs. Using SARS-CoV-2 amplicon-based sequencing, we assessed favipiravir’s impact on mutagenesis.

Results

We randomized 149 participants with 116 included in the mITT cohort. The participants’ mean age was 43 years (standard deviation, 12.5 years) and 57 (49%) were women. We found no difference in time to shedding cessation overall (hazard ratio [HR], 0.76 favoring placebo [95% confidence interval {CI}, .48–1.20]) or in subgroups (age, sex, high-risk comorbidities, seropositivity, or symptom duration at enrollment). We detected no difference in time to symptom resolution (initial: HR, 0.84 [95% CI, .54–1.29]; sustained: HR, 0.87 [95% CI, .52–1.45]) and no difference in transition mutation accumulation in the viral genome during treatment.

Conclusions

Our data do not support favipiravir at commonly used doses in outpatients with uncomplicated COVID-19. Further research is needed to ascertain if higher favipiravir doses are effective and safe for patients with COVID-19.

Clinical Trials Registration

NCT04346628.

抱歉!评论已关闭.

×
腾讯微博